Corvus Pharmaceuticals, Inc. CRVS
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. Based on the proposed mechanism of action, we believe soquelitinib has the potential to be utilized to inhibit the production of a number of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis and fibrotic diseases. In preclinical studies, Soquelitinib has affected T cell differentiation leading to enhanced function of T cells involved in tumor cell eradication.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $33.7M | $19.4M | $16.5M | $24.5M | $29.1M | $31.8M | $38.0M | $38.6M | $46.3M | $29.4M |
| SG&A | $9.3M | $8.2M | $6.9M | $8.1M | $9.5M | $11.9M | $10.9M | $10.6M | $10.2M | $7.6M |
| Total operating expenses | $43.0M | $27.5M | $23.4M | $32.6M | $38.6M | $43.8M | $48.9M | $49.2M | $56.5M | $37.0M |
| Operating income | -$43.0M | -$27.5M | -$23.4M | -$32.6M | -$38.6M | -$43.8M | -$48.9M | -$49.2M | -$56.5M | -$37.0M |
| Pre-tax income | -$13.3M | -$59.1M | -$21.7M | -$31.3M | -$43.2M | -$6.0M | -$46.7M | -$46.9M | -$55.7M | -$36.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.3M | -$62.3M | -$27.0M | -$41.3M | -$43.2M | -$6.0M | -$46.7M | -$46.9M | -$55.7M | -$36.4M |
| EPS, basic | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 | — | — | — |
| EPS, diluted | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 | -1.71 | -2.72 | -2.36 |
| Shares, diluted (wtd. avg.) | 79.7M | 61.0M | 48.0M | 46.6M | 41.9M | 29.5M | 29.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.6M | $8.7M | $12.6M | $13.2M | $63.5M | $16.5M | $5.2M | $39.2M | $45.1M | $5.0M |
| Short-term investments | $52.2M | $43.2M | — | — | — | — | — | — | — | — |
| Receivables | $37.0K | $75.0K | $26.0K | $588.0K | — | — | — | — | — | — |
| Total current assets | $58.2M | $54.4M | $28.0M | $43.7M | $71.3M | $45.3M | $79.3M | $115.6M | $91.2M | $136.0M |
| Property, plant and equipment | $220.0K | $151.0K | $236.0K | $353.0K | $451.0K | $906.0K | $1.5M | $2.2M | $2.7M | $3.2M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M | $85.5M | $83.6M | $118.2M | $94.8M | $140.2M |
| Accounts payable | $2.5M | $2.6M | $1.5M | $2.0M | $1.6M | $3.5M | $2.4M | $2.0M | $3.5M | $1.9M |
| Total current liabilities | $9.4M | $35.4M | $6.9M | $10.8M | $9.7M | $12.1M | $10.2M | $7.0M | $9.0M | $5.9M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M | $13.4M | $12.5M | $7.9M | $9.9M | $7.3M |
| Retained earnings | -$412.3M | -$397.0M | -$334.7M | -$307.7M | -$266.4M | -$223.1M | -$217.1M | -$170.5M | -$123.5M | -$67.9M |
| Total equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M | $72.1M | $71.1M | $110.3M | $84.8M | $132.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.8M | -$25.4M | -$23.9M | -$27.0M | -$36.7M | -$34.8M | -$37.3M | -$41.0M | -$46.2M | -$27.9M |
| Depreciation and amortisation | $105.0K | $85.0K | $151.0K | $367.0K | $460.0K | $632.0K | $743.0K | $847.0K | $842.0K | $594.0K |
| Stock-based compensation | $5.3M | $3.0M | $2.1M | $2.7M | $4.2M | $5.7M | $7.3M | $7.1M | $6.2M | $3.8M |
| Capital expenditure | $174.0K | — | $34.0K | $269.0K | $5.0K | $76.0K | $25.0K | $355.0K | $266.0K | $2.2M |
| Investing cash flow | -$7.8M | -$27.5M | $15.5M | -$23.3M | $21.6M | $44.8M | $3.3M | -$30.2M | $84.8M | -$42.6M |
| Financing cash flow | $36.4M | $49.0M | $7.9M | $0 | $62.2M | $1.3M | $24.0K | $65.3M | $1.4M | $71.4M |
| Dividends paid | $0 | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-048595.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$36.4M | -$55.7M | -$46.9M | -$46.7M | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |